<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003288</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01837</org_study_id>
    <secondary_id>POG-9675</secondary_id>
    <secondary_id>CDR0000066219</secondary_id>
    <nct_id>NCT00003288</nct_id>
  </id_info>
  <brief_title>Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors</brief_title>
  <official_title>A Trial of Tirapazamine and Cyclophosphamide in Children With Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of tirapazamine plus cyclophosphamide in treating&#xD;
      children who have refractory solid tumors. Drugs used in chemotherapy use different ways to&#xD;
      stop tumor cells from dividing so they stop growing or die. Combining more than one drug may&#xD;
      kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose and the dose limiting toxicity of tirapazamine when&#xD;
      administered with cyclophosphamide as intravenous infusions to children with refractory solid&#xD;
      tumors.&#xD;
&#xD;
      II. Determine the incidence and severity of other toxicities of tirapazamine and&#xD;
      cyclophosphamide in these patients.&#xD;
&#xD;
      III. Determine a safe and tolerable dose of tirapazamine administered with cyclophosphamide&#xD;
      for a phase II study for the same indications.&#xD;
&#xD;
      IV. Determine the pharmacokinetics of tirapazamine in children and adolescents receiving the&#xD;
      combination of tirapazamine and cyclophosphamide.&#xD;
&#xD;
      V. Determine the preliminary evidence of antitumor activity of tirapazamine and&#xD;
      cyclophosphamide.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      Patients receive tirapazamine by 2 hour intravenous infusion (hours 0-2) followed 2 hours&#xD;
      later by a 30 minute intravenous infusion of cyclophosphamide. This course is repeated every&#xD;
      3 weeks in patients with partial/complete response or stable disease for a maximum of 1 year.&#xD;
      Cohorts of 3-6 patients each are treated at each dose level of tirapazamine. Dose escalation&#xD;
      of tirapazamine occurs when 0 of 3 patients or 1 of 6 patients has experienced dose limiting&#xD;
      toxicity (DLT). If DLT is experienced in 1 of 3 patients at a given dose level, up to 3&#xD;
      additional patients are treated at that same dose level. If none of the 3 additional patients&#xD;
      at that dose level experiences DLT, the dose is escalated. If DLT is experienced in 1 or more&#xD;
      of the additional 3 patients, the maximum tolerated dose (MTD) has been exceeded and 3&#xD;
      patients are treated at the next lower dose level (defined as the MTD). A total of six&#xD;
      patients are treated at the MTD. If DLT is proved to be neutropenia, patients must then also&#xD;
      meet the additional eligibility criteria listed for stratum 2. If neutropenia continues to be&#xD;
      the DLT in stratum 2, then additional patients receive subcutaneous filgrastim (granulocyte&#xD;
      colony-stimulating factor; G-CSF) beginning 24 hours after cyclophosphamide. A second MTD may&#xD;
      be determined for chemotherapy with G-CSF. Patients are followed every 6 months for 4 years,&#xD;
      and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1998</start_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See arm description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tirapazamine</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumor that is refractory to conventional therapy or for&#xD;
             which no effective therapy is known&#xD;
&#xD;
          -  Brain tumors eligible Brainstem gliomas may waive histological verification&#xD;
             requirement&#xD;
&#xD;
          -  Neurologic deficits associated with CNS malignancies must be stable for a minimum of 4&#xD;
             weeks prior to study&#xD;
&#xD;
          -  No leukemia Stratum 2&#xD;
&#xD;
          -  No marrow involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Age: 21 and under&#xD;
&#xD;
          -  Performance status: Karnofsky or Lansky 50-100%&#xD;
&#xD;
          -  Life expectancy: At least 8 weeks&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  SGPT less than 5 times normal&#xD;
&#xD;
          -  Creatinine normal for age OR creatinine clearance at least 70 mL/min&#xD;
&#xD;
          -  Shortening fraction at least 27% of normal OR ejection fraction greater than 50% of&#xD;
             normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test required&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No concurrent anticancer therapy&#xD;
&#xD;
          -  At least 6 months since bone marrow transplant and no evidence of graft versus host&#xD;
             disease&#xD;
&#xD;
          -  At least 1 week since growth factors&#xD;
&#xD;
          -  No concurrent granulocyte colony-stimulating factor&#xD;
&#xD;
          -  Recovered from prior immunotherapy&#xD;
&#xD;
          -  Stratum 2: No prior bone marrow transplantation (with or without total body&#xD;
             irradiation)&#xD;
&#xD;
          -  At least 6 weeks since prior nitrosourea&#xD;
&#xD;
          -  At least 2 weeks since other prior myelosuppressive chemotherapy&#xD;
&#xD;
          -  Dexamethasone must be a stable or decreasing dose for 2 weeks prior to study&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  Stratum 2: No more than 2 prior chemotherapy regimens&#xD;
&#xD;
          -  At least 2 weeks since local palliative radiotherapy (small port)&#xD;
&#xD;
          -  At least 6 months since prior substantial bone marrow radiation (e.g., cross-&#xD;
             sectional radiotherapy [greater than 24 Gy], total body irradiation, hemi- pelvic&#xD;
             radiotherapy)&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  Stratum 2: No prior central axis radiation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor Aquino, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvester Cancer Center, University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital - Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital, Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160-7357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Oncology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Floating Hospital for Children</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216-4505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York - Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105-2794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-9154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2000</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>September 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2004</study_first_posted>
  <last_update_submitted>February 4, 2013</last_update_submitted>
  <last_update_submitted_qc>February 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tirapazamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

